Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 13/20 | 0.60 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4767142 | 0.89 | DPP4 (0.53) | RORCROCK2L3MBTL1NPC1NFKB1 | |
| SCHEMBL4770984 | 0.88 | RORC (0.54) | RORCROCK2NPC1RAB9AKMT2A | |
| SCHEMBL4767859 | 0.85 | RORC (0.47) | RORCROCK2RAB9ASMN1; SMN2 | |
| SCHEMBL4772670 | 0.84 | NPC1 (0.71) | RORCNPC1NFKB1HTTRAB9A | |
| SCHEMBL4767344 | 0.84 | TDP1 (0.58) | L3MBTL1NPC1NFKB1HTTRAB9A | |
| SCHEMBL4772154 | 0.84 | NPC1 (0.52) | RORCL3MBTL1NPC1NFKB1HTT | |
| SCHEMBL4773028 | 0.84 | RAB9A (0.60) | NPC1NFKB1RAB9ANFKB2KMT2A | |
| SCHEMBL4770633 | 0.83 | HRH3 (0.64) | NPC1NFKB1HTTRAB9ANFKB2 | |
| SCHEMBL4775935 | 0.82 | EPHX1 (0.48) | ROCK2NPC1HTTRAB9AKMT2A | |
| SCHEMBL4772145 | 0.82 | MAPK14 (0.53) | NPC1NFKB1HTTRAB9ANFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713778-B1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-16 | — | — | EP | claimed |
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | GLAXO GROUP LIMITED (GB) | 2007-03-15 | — | — | US | claimed |
| EP-1713778-B1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | HRH3, HRH4, HRH1 | RORC 1661/4885ROCK2 3702/4885L3MBTL1 1581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.